Behavioral Effects of d-Amphetamine in Humans: Influence of Subclinical Levels of Inattention and Hyperactivity

REFERENCES

• Froehlich TE, Lanphear BP, Epstein JN, Barbaresi WJ, Katusic SK, Kahn RS. Prevalence, recognition, and treatment of attention-deficit/hyperactivity disorder in a national sample of U.S. children. Arch Pediatr Adolesc Med 2007; 161(9):857–864.
   PubMed Web of Science ®Google Scholar
• Clure C, Brady KT, Saladin ME, Johnson D, Waid R, Rittenbury M. Attention-deficit/hyperactivity disorder and substance use: symptom pattern and drug choice. Am J Drug Alcohol Abuse 1999; 25(3):441–448.
   PubMed Web of Science ®Google Scholar
• Biederman J, Wilens T, Mick E, Spencer T, Faraone SV. Pharmacotherapy of attention-deficit/hyperactivity disorder reduces risk for substance use disorder. Pediatrics 1999; 104(2):e20.
   PubMed Web of Science ®Google Scholar
• Pomerleau OF, Downey KK, Stelson FW, Pomerleau CS. Cigarette smoking in adult patients diagnosed with attention deficit hyperactivity disorder. J Subst Abuse 1995; 7(3):373–378.
   PubMedGoogle Scholar
• Carroll KM, Rounsaville BJ. History and significance of childhood attention deficit disorder in treatment-seeking cocaine abusers. Compr Psychiatry 1993; 34(2):75–82.
   PubMed Web of Science ®Google Scholar
• Kollins SH, English J, Robinson R, Hallyburton M, Chrisman AK. Reinforcing and subjective effects of methylphenidate in adults with and without attention deficit hyperactivity disorder (ADHD). Psychopharmacology (Berl) 2009; 204(1):73–83.
   PubMed Web of Science ®Google Scholar
• Saules KK, Pomerleau CS, Schubiner H. Patterns of inattentive and hyperactive symptomatology in cocaine-addicted and non-cocaine-addicted smokers diagnosed with adult attention deficit hyperactivity disorder. J Addict Dis 2003; 22(2):71–78.
   PubMed Web of Science ®Google Scholar
• Cocores JA, Davies RK, Mueller PS, Gold MS. Cocaine abuse and adult attention deficit disorder. J Clin Psychiatry 1987; 48(9):376–377.
   PubMed Web of Science ®Google Scholar
• Kollins SH, McClernon FJ, Fuemmeler BF. Association between smoking and attention-deficit/hyperactivity disorder symptoms in a population-based sample of young adults. Arch Gen Psychiatry 2005; 62(10):1142–1147.
   PubMed Web of Science ®Google Scholar
• Fuemmeler BF, Kollins SH, McClernon FJ. Attention deficit hyperactivity disorder symptoms predict nicotine dependence and progression to regular smoking from adolescence to young adulthood. J Pediatr Psychol 2007; 32(10):1203–1213.
   PubMed Web of Science ®Google Scholar
• Fischman MW, Foltin RW. Utility of subjective-effects measurements in assessing abuse liability of drugs in humans. Br J Addict 1991; 86(12):1563–1570.
   PubMedGoogle Scholar
• Rush CR, Stoops WW, Hays LR, Glaser PE, Hays LS. Risperidone attenuates the discriminative-stimulus effects of d-amphetamine in humans. J Pharmacol Exp Ther 2003; 306(1):195–204.
   PubMed Web of Science ®Google Scholar
• Lile JA, Stoops WW, Vansickel AR, Glaser PE, Hays LR, Rush CR. Aripiprazole attenuates the discriminative-stimulus and subject-rated effects of D-amphetamine in humans. Neuropsychopharmacology 2005a; 30(11):2103–2114.
   PubMed Web of Science ®Google Scholar
• Lile JA, Stoops WW, Wagner FP, Glaser PE, Rush CR. Oxazepam does not modulate the behavioral effects of d-amphetamine in humans. Pharmacol Biochem Behav 2005b; 82(2):270–279.
   PubMed Web of Science ®Google Scholar
• Rush CR, Stoops WW, Wagner FP, Hays LR, Glaser PE. Alprazolam attenuates the behavioral effects of d-amphetamine in humans. J Clin Psychopharmacol 2004; 24(4):410–420.
   PubMed Web of Science ®Google Scholar
• Stoops WW, Lile JA, Glaser PE, Rush CR. A low dose of aripiprazole attenuates the subject-rated effects of d-amphetamine. Drug Alcohol Depend 2006; 84(2):206–209.
   PubMed Web of Science ®Google Scholar
• Stoops WW, Lile JA, Glaser PE, Rush CR. Effects of fluphenazine on the discriminative-stimulus and subject-rated effects of d-amphetamine. Unpublished data.
   Google Scholar
• Jones HE, Griffiths RR. Oral caffeine maintenance potentiates the reinforcing and stimulant subjective effects of intravenous nicotine in cigarette smokers. Psychopharmacology (Berl) 2003; 165(3):280–290.
   PubMed Web of Science ®Google Scholar
• Vansickel AR, Lile JA, Stoops WW, Rush CR. Similar discriminative-stimulus effects of D-amphetamine in women and men. Pharmacol Biochem Behav 2007; 87(2):289–296.
   PubMed Web of Science ®Google Scholar
• Oliveto AH, Bickel WK, Hughes JR, Shea PJ, Higgins ST, Fenwick JW. Caffeine drug discrimination in humans: Acquisition, specificity and correlation with self-reports. J Pharmacol Exp Ther 1992; 261(3):885–894.
   PubMed Web of Science ®Google Scholar
• Di Marino ME, Haberny KA, Felch LJ, Walsh SL, Preston KL, Bigelow GE. Development of a subjective rating scale sensitive to acute cocaine administration. National Institute on Drug Abuse Research Monograph Series, Problems of Drug Dependence, 1997: Proceedings of the 59th Annual Scientific Meeting 1998; 178:139.
   Google Scholar
• Jasinski D. Assessment of the abuse potentiality of morphine-like drugs (methods used in man). In Drug Addiction I. Martin WR, ed. New York, NY: Springer-Verlag Inc., 1977; pp. 197–258.
   Google Scholar
• Martin WR, Sloan JW, Sapira JD, Jasinski DR. Physiologic, subjective, and behavioral effects of amphetamine, methamphetamine, ephedrine, phenmetrazine, and methylphenidate in man. Clin Pharmacol Ther 1971; 12(2):245–258.
   PubMed Web of Science ®Google Scholar
• Saladin ME, Brady KT, Dansky BS, Kilpatrick DG. Understanding comorbidity between PTSD and substance abuse disorders: Two preliminary investigations. Addict Behav 1995; 20(5):643–655.
   PubMed Web of Science ®Google Scholar
• Sevak RJ, Stoops WW, Hays LR, Rush CR. Discriminative-stimulus and subject-rated effects of methamphetamine, d-amphetamine, methylphenidate, and triazolam in methamphetamine-trained humans. J Pharmacol Exp Ther 2009; 328(3):1007–1018.
   PubMed Web of Science ®Google Scholar
• Stoops WW, Lile JA, Glaser PE, Rush CR. Discriminative stimulus and self-reported effects of methylphenidate, d-amphetamine, and triazolam in methylphenidate-trained humans. Exp Clin Psychopharmacol 2005; 13(1):56–64.
   PubMed Web of Science ®Google Scholar
• Chait LD, Uhlenhuth EH, Johanson CE. The discriminative stimulus and subjective effects of phenylpropanolamine, mazindol and d-amphetamine in humans. Pharmacol Biochem Behav 1986; 24(6):1665–1672.
   PubMed Web of Science ®Google Scholar
• Rush CR, Kollins SH, Pazzaglia PJ. Discriminative-stimulus and participant-rated effects of methylphenidate, bupropion, and triazolam in d-amphetamine-trained humans. Exp Clin Psychopharmacol 1998; 6(1):32–44.
   PubMed Web of Science ®Google Scholar
• Schuster CR, Johanson CE. Relationship between the discriminative stimulus properties and subjective effects of drugs. Psychopharmacol Ser 1988; 4:161–175.
   PubMedGoogle Scholar
• Kelly TH, Stoops WW, Perry AS, Prendergast MA, Rush CR. Clinical neuropharmacology of drugs of abuse: A comparison of drug-discrimination and subject-report measures. Behav Cogn Neurosci Rev 2003; 2(4):227–260.
   PubMedGoogle Scholar
• Boileau I, Dagher A, Leyton M, Gunn RN, Baker GB, Diksic M, Benkelfat C. Modeling sensitization to stimulants in humans: An [11C]raclopride/positron emission tomography study in healthy men. Arch Gen Psychiatry 2006; 63(12):1386–1395.
   PubMed Web of Science ®Google Scholar
• Rosa-Neto P, Lou HC, Cumming P, Pryds O, Karrebaek H, Lunding J, Gjedde A. Methylphenidate-evoked changes in striatal dopamine correlate with inattention and impulsivity in adolescents with attention deficit hyperactivity disorder. Neuroimage 2005; 25(3):868–876.
   PubMed Web of Science ®Google Scholar
• Armstrong TD, Costello EJ. Community studies on adolescent substance use, abuse, or dependence and psychiatric comorbidity. J Consult Clin Psychol 2002; 70(6):1224–1239.
   PubMed Web of Science ®Google Scholar